|
AT-GC's primary focus is to
discover, develop and market gene based immunotherapeutic products that improve
human health. Our Commercialization map is the result of an intensive focus on
validated discovery and targeted partnership programs. Effective management of
preclinical and clinical programs leads to a natural and necessary
prioritization of product candidates. Experimental compounds undergo rigorous
safety and efficacy testing, the results of which determine the fate of each
program. Whether directed at cancer, infectious disease or multi drug resistant
infections, our drug candidates reflect the company's therapeutic strengths:
development of preventative and therapeutic vaccines and associated adjuvant
compounds, select development of monoclonal antibody therapies, and discovery
and development of compounds to stimulate innate immunity. We believe that
validated discovery, productive partnerships and consistent clinical and
regulatory execution will make AT-GC's commercialization goals and reality.
Vaccines were
among the biggest medical breakthroughs of the 20th century. In the past 2
years, more than 15 new gene and immunotherapy medicines have come to market and
at least 25 products are in late stage clinical trials.
Key focus area for AT-GC are:
1. Markets and advancements in:
preventative pediatric
vaccines
adult at-risk vaccines
therapeutic vaccines
(including those based on antibodies, immunoproteins, DNA epitopes)
2. Delivery systems engineered to target
diseased cells as well as maximum prophylactic and therapeutic efficiency
3. Disease
vaccine development for:
cancer
infectious diseases
multi drug resistant
infections
Biodefense
|
|
